Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis

Acta Pharmacologica Sinica

Volumn 32, Issue 6, 2011, Pages 693-701

  Cai, Zhi Wei ^a   Liu, Jia ^a   Li, Hong Yu ^a   Sheppard, David N ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

ATP binding cassette transporter; CFTR; CFTR corrector; CFTR potentiator; chloride ion channel; cystic fi brosis; epithelial ion transport; F508del

Indexed keywords

2 (2 CHLOROBENZAMIDO) 4,5,6,7 TETRAHYDRO 3H INDENE 1 CARBOXAMIDE; 4 CYCLOHEXYLOXY 2 [1 [4 (4 METHOXYBENZENESULFONYL)PIPERAZIN 1 YL]ETHYL]QUINAZOLINE; 4 METHYL 2 (5 PHENYL 1H PYRAZOL 3 YL)PHENOL; 5 (4 NITROPHENYL) 2 FURALDEHYDE 2 PHENYLHYDRAZONE; BENZAMIDE DERIVATIVE; GENISTEIN; INDENE DERIVATIVE; IVACAFTOR; N [2 (5 CHLORO 2 METHOXYPHENYLAMINO) 4' METHYL[4,5']BITHIAZOLYL 2' YL]BENZAMIDE; PHENYLHYDRAZONE DERIVATIVE; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; RD 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VRT 325; VRT 532;

CHANNEL GATING; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG TARGETING; GENE MUTATION; HUMAN; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN TARGETING; WATER TRANSPORT;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION CHANNEL GATING; MOLECULAR STRUCTURE; MUTATION; PROTEIN TRANSPORT; SMALL MOLECULE LIBRARIES;

EID: 79958088886     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.71     Document Type: Conference Paper

References (73)

1. Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill Inc; 2001. p 5121-88.
2. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-82.
3. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001. (Pubitemid 40638370)
4. Boucher RC. Airway surface dehydration in cystic fibrosis: patho-genesis and therapy. Annu Rev Med 2007;58:157-70. (Pubitemid 46706507)
5. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73. (Pubitemid 19231814)
6. Holland IB, Cole S P C, Kuchler K, Higgins CF. ABC Proteins: from bacteria to man. London: Academic Press; 2003.
7. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science. 1991;253:202-5. (Pubitemid 21917143)
8. Bear CE, Li CH, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992;68:809-18.
9. Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991;67:775-84. (Pubitemid 121001490)
10. Hwang TC, Nagel G, Nairn AC, Gadsby DC. Regulation of the gating of cystic fibrosis transmembrane conductance regulator C1 channels by phosphorylation and ATP hydrolysis. Proc Natl Acad Sci U S A 1994;91:4698-702. (Pubitemid 24177716)
11. Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, Jefferson DM, et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990;347:358-63.
12. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827-34. (Pubitemid 120035055)
13. Drumm ML, Wilkinson DJ, Smit LS, Worrell RT, Strong TV, Frizzell RA, et al. Chloride conductance expressed by ΔF508 and other mutant CFTRs in Xenopus oocytes. Science 1991;254:1797-9. (Pubitemid 21917530)
14. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, et al. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature 1991;354:526-8. (Pubitemid 21896832)
15. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999;79(1 Suppl): S23-45. (Pubitemid 29058908)
16. Li C, Ramjeesingh M, Reyes E, Jensen T, Chang X, Rommens JM, et al. The cystic fibrosis mutation (ΔF508) does not influence the chloride channel activity of CFTR. Nat Genet 1993;3:311-6. (Pubitemid 23112955)
17. - channel. J Gen Physiol 2003;122:605-20. (Pubitemid 37420853)
18. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992;358:761-4.
19. French PJ, van Doorninck JH, Peters RH, Verbeek E, Ameen NA, Marino CR, et al. A ΔF508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest 1996;98:1304-12. (Pubitemid 26322055)
20. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, et al. ΔF508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol 1996;270: C1544-55.
21. Hwang TC, Wang F, Yang IC, Reenstra WW. Genistein potentiates wild-type and ΔF508-CFTR channel activity. Am J Physiol 1997;273: C988-98. (Pubitemid 27422179)
22. Schultz BD, Frizzell RA, Bridges RJ. Rescue of dysfunctional ΔF508-CFTR chloride channel activity by IBMX. J Membr Biol 1999;170:51-66. (Pubitemid 29329947)
23. Cai Z, Sheppard DN. Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity. J Biol Chem 2002;277:19546-53. (Pubitemid 34967467)
24. Miki H, Zhou Z, Li M, Hwang TC, Bompadre SG. Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs. J Biol Chem 2010;285:19967-75.
25. Wang F, Zeltwanger S, Hu S, Hwang TC. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 2000;524:637-48. (Pubitemid 30303615)
26. Roxo-Rosa M, Xu Z, Schmidt A, Neto M, Cai Z, Soares CM, et al. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci U S A 2006;103:17891-6. (Pubitemid 44852256)
27. - channels. J Gen Physiol 2003;121:17-36. (Pubitemid 36133934)
28. Vergani P, Lockless SW, Nairn AC, Gadsby DC. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 2005;433:876-80. (Pubitemid 40314897)
29. Locher KP, Lee AT, Rees DC. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 2002;296:1091-8. (Pubitemid 34517120)
30. Smith PC, Karpowich N, Millen L, Moody JE, Rosen J, Thomas PJ, et al. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 2002;10:139-49. (Pubitemid 34876568)
31. Lewis HA, Buchanan SG, Burley SK, Conners K, Dickey M, Dorwart M, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis trans membrane conductance regulator. EMBO J 2004;23:282-93. (Pubitemid 38294493)
32. Lewis HA, Zhao X, Wang C, Sauder JM, Rooney I, Noland BW, et al. Impact of the ΔF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem 2005;280:1346-53.
33. Aleksandrov L, Aleksandrov AA, Chang XB, Riordan JR. The first nucleotide binding domain of cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a site of rapid turnover. J Biol Chem 2002;277:15419-25. (Pubitemid 34967805)
34. 2-terminal nucleotide binding domain and its role in channel gating. J Gen Physiol 2003;122:333-48. (Pubitemid 37163281)
35. Gadsby DC, Vergani P, Csanády L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006;440:477-83
36. - channel by ATP-driven nucleotide-binding domain dimerisation. J Physiol 2009;587:2151-61.
37. Kirk K, Wang W. A unified view of cystic fibrosis transmembrane conductance regulator (CFTR) gating: combining the allosterism of a ligand-gated channel with the enzymatic activity of an ATP-binding cassette (ABC) transporter. J Biol Chem 2011;286:12813-9
38. Pissarra LS, Farinha CM, Xu Z, Schmidt A, Thibodeau PH, Cai Z, et al. Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem Biol 2008;15:62-9
39. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006 14; 443:180-5 (Pubitemid 44387602)
40. Serohijos AW, Hegedus T, Aleksandrov AA, He L, Cui L, Dokholyan NV et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channe function. Proc Natl Acad Sci U S A 2008;105:3256-61 (Pubitemid 351723540)
41. Mornon JP, Lehn P, Callebaut I. Atomic model of human cystic fibrosis trans membrane conductance regulator: membrane-spanning domains and coupling interfaces. Cell Mol Life Sci 2008;65:2594-612
42. Mornon JP, Lehn P, Callebaut I. Molecular models of the open and closed states of the whole human CFTR protein. Cell Mol Life Sc 2009;66:3469-86
43. Alexander C, Ivetac A, Liu X, Norimatsu Y, Serrano JR, Landstrom A, et al. Cystic fibrosis transmembrane conductance regulator: using differential reactivity toward channel-permeant and channel-mpermeant thiol-reactive probes to test a molecular model for the pore. Biochemistry 2009;48:10078-88
44. Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A, Riordan JR et al. The AF508 mutation decreases the stability of cystic fibrosis trans membrane conductance regulator in the plasma membrane Deter mination of functional half-lives on transfected cells. J Bio Chem 1993;268:21592-8 (Pubitemid 23320650)
45. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009;8:153-71
46. Amaral MD. Targeting CFTR: How to treat cystic fibrosis by CFTR-repairing therapies. Curr Drug Targets. 2011;12:683-93
47. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science 2008;319:916-9 (Pubitemid 351263754)
48. Becq F, Jensen TJ, Chang XB, Savoia A, Rommens JM, Tsui LC, et al. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci U S A 1994;91:9160-4
49. Kalid O, Mense M, Fischman S, Shitrit A, Bihler H, Ben-Zeev E, et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 2010;24:971-91
50. Pedemonte N, Tomati V, Sondo E, Caci E, Millo E, Armirotti A, et al. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel caused by cystic fibrosis mutations. J Bio Chem 2011;286:15215-26
51. Pedemonte N, Diena T, Caci E, Nieddu E, Mazzei M, Ravazzolo R, et al. Antihypertensive 1, 4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 2005;68:1736-46 (Pubitemid 41654357)
52. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, et al. Nanomolar affinity small molecule correctors of defective AF508-CFTR chloride channel gating. J Biol Chem 2003;278:35079-85 (Pubitemid 37102270)
53. Xu LN, Na WL, Liu X, Hou SG, Lin S, Yang H, et al. Identification of natural coumarin compounds that rescue defective ΔF508-CFTR chloride channel gating. Clin Exp Pharmacol Physiol 2008;35:878-83. (Pubitemid 351951949)
54. Sheppard DN, Carson MR, Ostedgaard LS, Denning GM, Welsh MJ. Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium. Am J Physiol 1994;266: L405-13.
55. Van Goor F, Straley KS, Cao D, González J, Hadida S, Hazlewood A, et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290: L1117-30. (Pubitemid 43830856)
56. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115:2564-71. (Pubitemid 41266219)
57. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, Bear CE. A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 2010;78:411-8.
58. Sampson HM, Robert R, Liao J, Matthes E, Carlile GW, Hanrahan JW, et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol. 2011;18:231-42.
59. Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008;73:478-89. (Pubitemid 351159218)
60. Robert R, Carlile GW, Liao J, Balghi H, Lesimple P, Liu N, et al. Correction of the ΔF508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol. 2010;77:922-30.
61. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, et al. Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005;67:1797-807. (Pubitemid 40594181)
62. Pedemonte N, Boido D, Moran O, Giampieri M, Mazzei M, Ravazzolo R, et al. Structure-activity relationship of 1, 4-dihydropyridines as poten-tiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol Pharmacol 2007;72:197-207. (Pubitemid 46998539)
63. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009;106:18825-30.
64. - channel. J Biol Chem 2006;281:1970-7. (Pubitemid 43845783)
65. Bompadre SG, Sohma Y, Li M, Hwang TC. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J Gen Physiol 2007;129:285-98. (Pubitemid 46506980)
66. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR muta tion. N Engl J Med 2010;363:1991-2003.
67. Ai T, Bompadre SG, Wang X, Hu S, Li M, Hwang TC. Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol Pharmacol 2004;65:1415-26. (Pubitemid 38668300)
68. Moran O, Galietta LJ, Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 2005;62:446-60. (Pubitemid 40379235)
69. Wang F, Zeltwanger S, Yang IC, Nairn AC, Hwang TC. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 1998;111:477-90. (Pubitemid 28136466)
70. Zegarra-Moran O, Monteverde M, Galietta LJ, Moran O. Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators. Interaction between activation and inhibition. J Biol Chem 2007;282:9098-104. (Pubitemid 47093516)
71. - channels expressed in mammalian cells. J Physiol 1998;508:379-92. (Pubitemid 28203954)
72. de Jonge H, Wilke M, Bot A, Sheppard DN. Responsiveness of mouse versus human CFTR-ΔF508 to small molecule correctors and poten-tiators. Pediatr Pulmonol Suppl 2009;32:291-92.
73. - channel with the gating behavior of murine CFTR. Proc Natl Acad Sci U S A 2007;104:16365-70. Acta Pharmacologica Sinica (Pubitemid 350099410)